To ask the Secretary of State for Health with reference to his Department's announcement of 1 November 2010 on the future role of the National Institute for Health and Clinical Excellence, whether the cost-effectiveness element of the health technology appraisal will be phased out prior to the planned introduction of value-based pricing.
Prior to the proposed introduction of value-based drug pricing from January 2014, we expect that the National Institute for Health and Clinical Excellence (NICE) will continue to appraise the clinical and cost-effectiveness of specific drugs and treatments.
Our plans for value-based pricing aim to ensure that clinically effective drugs are also cost-effective, with the national health service paying a price that reflects the value of a drug to patients. As we develop and implement our plans for value-based drug pricing, NICE's role will inevitably evolve with NICE continuing to have an important advisory role, including in assessing the clinical benefits of new medicines. We will be consulting shortly on our plans for value-based pricing.